Walleye Capital
MIST icon

Walleye Capital’s Milestone Pharmaceuticals MIST Stock Holding History

Walleye Capital’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,109
Closed -$29.3K – 4875
2025
Q2 		$29.3K Sell
15,109
-76,811
-84% -$102K ﹤0.01% 4176
2025
Q1 		$73.5K Buy
+91,920
New +$183K ﹤0.01% 3729
2023
Q1 		– Sell
-81,660
Closed -$323K – 4207
2022
Q4 		$323K Buy
+81,660
New +$430K 0.01% 1734

Other funds holding MIST

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Walleye Capital's MIST Position: Q3 2025 in Review

Walleye Capital sold out of Milestone Pharmaceuticals (MIST) in Q3 2025, closing a stake of 15,109 shares — an estimated $29.3K sold.

Walleye Capital first reported a position in MIST in Q4 2022 and held it in 3 quarters. The position peaked at $323K in Q4 2022. 61 funds tracked by Wall St. Rank hold MIST as of Q3 2025.

  • Walleye Capital reported no remaining Milestone Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Walleye Capital sold 15,109 Milestone Pharmaceuticals shares in Q3 2025, an estimated $29.3K.
  • Walleye Capital first reported a position in Milestone Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Walleye Capital's Milestone Pharmaceuticals position peaked at $323K in Q4 2022.
  • 61 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.